Published on October 31st, 20190
Gold Shield Group
TINA.org obtained the letters through a Freedom of Information Act request. One of the firms was Gold Shield Group.
Here’s what one of the Gold Shield Group TV ads cited in the letter said:
Attention, Type 2 diabetics. Invokana, Invokamet, Jardiance, and Farxiga are linked to an increased risk of toe, leg, and foot amputations. The FDA has also warned of links to genital gangrene, also known as Fournier’s gangrene or ketoacidosis.
And what the FTC said:
We note that the FDA describes gangrene of the genital area as a rare side effect. Accordingly, the implication that these products pose a substantial risk of gangrene of the genital area appears to be false. In addition, this ad may convey to a significant number of viewers that taking Invokana, Invokamet, Jardiance, or Farxiga poses a substantial risk of toe, leg, and foot amputations and that the risks from taking these medicines outweigh their benefits. Unless you have competent and reliable scientific evidence to support such claims, you should not make them.
Find more of our coverage on pharmaceuticals here.